How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,542 results for

Neurology Books

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V

Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Larotrectinib (solide Tumore mit einer neurotrophen Tyrosin-Rezeptor-Kinase [NTRK]-Genfusion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 January 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract IQWiG Reports – Commission No. A19-90 Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-90 Version 1.0 Larotrectinib (solid tumours with NTRK gene fusion) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Larotrectinib (solid tumours

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

2. Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V

Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Galcanezumab (Migräne) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-28 Galcanezumab (migraine (...) ) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-28 Version 1.0 Galcanezumab (migraine) 27 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Galcanezumab (migraine) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 March 2019 Internal Commission No.: A19-28 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V

Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Cladribin (multiple Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-62 (...) Cladribine (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-62 Version 1.0 Cladribine (multiple sclerosis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cladribine (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V

Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Erenumab (Migräne) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 January 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A18-71 Erenumab (migraine) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-71 Version 1.0 Erenumab (migraine) 30 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Erenumab (migraine) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 October 2018

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V

Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Perampanel (Epilepsie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-61 Perampanel (epilepsy (...) ) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-61 Version 1.0 Perampanel (epilepsy) 26 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Perampanel (epilepsy) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 30 November 2017 Internal Commission No.: A17-61 Address

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V

Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Glycopyrroniumbromid (Sialorrhö) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A18-22 Glycopyrronium bromide (sialorrhoea) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-22 Version 1.0 Glycopyrronium bromide (sialorrhoea) 27 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Glycopyrronium bromide (sialorrhoea) – Benefit assessment according to §35a Social Code Book V Commissioning agency

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Extrakt aus Cannabis sativa (Spastik aufgrund von multipler Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 26 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG (...) to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-27 Extract from Cannabis sativa (spasticity due to multiple sclerosis) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-27 Version 1.0 Extract from Cannabis sativa (spasticity due to multiple sclerosis) 26 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

8. Neurology Books

Neurology Books Neurology Books Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Neurology Books Neurology Books Aka: Neurology Books (...) , Neurology References II. Resources: Medical Student Library Recommendations O'Brien (2010) Exam of the Peripheral Nervous System, Saunders Goldberg (2012) Four Minute (Made Ridiculously Simple) Goldberg (2014) Clinical Made Ridiculously Simple Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Neurology Books." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database

2018 FP Notebook

9. Safinamide: benefit assessment according to §35a Social Code Book V (dossier assessment)

Safinamide: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Safinamid – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 August 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-18 Safinamide – Benefit assessment (...) according to §35a Social Code Book V 1 Extract of dossier assessment A15-18 Version 1.0 Safinamide – Benefit assessment acc. to §35a Social Code Book V 13 August 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Safinamide – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 May 2015 Internal Commission No.: A15-18

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Fingolimod (neues Anwendungsgebiet – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 September 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A14-21 Fingolimod (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-21 Version 1.0 Fingolimod (new TI) – Benefit assessment acc. to §35a SGB V 26 September 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Fingolimod (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. The "Neurological Hat Game": A fun way to learn the neurological semiology. (Abstract)

The "Neurological Hat Game": A fun way to learn the neurological semiology. In-class courses are deserted by medical students who tend to find it more beneficial to study in books and through online material. New interactive teaching methods, such as serious games increase both performance and motivation. We developed and assessed a new teaching method for neurological semiology using the "Hat Game" as a basis.In this game, two teams of second-year medical students are playing against one (...) another. The game is played with a deck of cards. A neurological symptom or sign is written on each card. Each team gets a predefined period of time to guess as many words as possible. One member is the clue-giver and the others are the guessers. There are three rounds: during the first round, the clue-giver uses any descriptive term he wants and as many as he wants to make his team guess the maximum number of words within the allocated time. During the second round, the clue-giver can only choose one

2019 Revue Neurologique Controlled trial quality: uncertain

12. Perampanel (epilepsy and seizures) ? Benefit assessment according to §35a Social Code Book V

Perampanel (epilepsy and seizures) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Perampanel – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 August 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14-16 Perampanel – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-16 Version 1.0 Perampanel – Benefit assessment acc. to §35a Social Code Book V 13 August 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Perampanel – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 9 May 2014 Internal Commission

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V

Dimethyl fumarate (multiple sclerosis ? relapsing-remitting) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dimethylfumarat – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14 (...) -14 Dimethyl fumarate – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-14 Version 1.0 Dimethyl fumarate – Benefit assessment acc. to §35a Social Code Book V 30 July 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dimethyl fumarate – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Digitally enabled aged care and neurological rehabilitation to enhance outcomes with Activity and MObility UsiNg Technology (AMOUNT) in Australia: A randomised controlled trial Full Text available with Trip Pro

Digitally enabled aged care and neurological rehabilitation to enhance outcomes with Activity and MObility UsiNg Technology (AMOUNT) in Australia: A randomised controlled trial Digitally Enabled Aged Care and Neurological Rehabilitation to Enhance Outcomes With Activity and MObility UsiNg Technology (AMOUNT) in Australia: A Randomised Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) : Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation PLoS Med Actions . 2020 Feb 18;17(2):e1003029. doi: 10.1371/journal.pmed.1003029. eCollection 2020 Feb. Digitally Enabled Aged Care and Neurological Rehabilitation to Enhance Outcomes With Activity and MObility UsiNg Technology (AMOUNT) in Australia: A Randomised Controlled Trial , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

15. Rilpivirine - Benefit assessment according to § 35a Social Code Book V

was rated as severe/serious symptoms. For antiretroviral-naïve adult women with an HIV-1 infection and a viral load of = 100,000 HIV-1 RNA copies/ml there was an indication of lesser harm for the outcome “neurological events”. The extent of the respective added benefit at outcome level was estimated from these results (see Table 15). Extract of dossier assessment A12-04 Version 1.0 Rilpivirine – Benefit assessment acc. to § 35a Social Code Book V 12.04.2012 Institute for Quality and Efficiency in Health (...) Rilpivirine - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (”Rilpvirin – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 12.04.2012). In the present extract, references to Sections 2.7 onwards relate to the full version of the assessment report (hereinafter called the “full dossier assessment”). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Extract from Cannabis sativa - Benefit assessment according to § 35a Social Code Book V

Extract from Cannabis sativa - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 29.03.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract from Cannabis sativa – Benefit assessment (...) according to § 35a Social Code Book V 1 Extract of dossier assessment A12-01 Version 1.0 Extract from Cannabis sativa – Benefit assessment acc. to § 35a SGB V 29.03.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Extract from Cannabis sativa – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 02.01.2012 Internal

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Rilpivirine/emtricitabine/tenofovir - Benefit assessment according to § 35a Social Code Book V

Rilpivirine/emtricitabine/tenofovir - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Rilpivin/Emcitricitabin/Tenofovir – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 12.04.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Report – Commission No. A12-02 (...) Rilpivirine/emtricitabine/tenofovir – Benefit assessment according to § 35a Social Code Book V 1 Extract of dossier assessment A12-02 Version 1.0 Rilpivirine/emtricitabine/tenofovir – Benefit assessment acc. to § 35a SGB V 12.04.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Rilpivirine/emtricitabine/tenofovir – Benefit assessment according to § 35a SGB V Contracting agency: Federal Joint

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Tafamidis meglumine - Benefit assessment according to § 35a Social Code Book V

– Benefit assessment acc. to § 35a Social Code Book V 13.03.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Thomas Henze, Rehabilitation Hospital for Neurology, Geriatrics and Urology, Nittenau, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. Individual sections and conclusions in the dossier assessment (...) . Morbidity Neurological impairment (NIS-LL response) A responder analysis was used for the benefit assessment for the outcome “neurological impairment”, measured with the NIS-LL (for detailed reasoning, see Section 2.7.2.4.3 of the full dossier assessment). In this analysis, response is defined as an increase of less than 2 Extract of dossier assessment A11-31 Version 1.0 Tafamidis meglumine – Benefit assessment acc. to § 35a Social Code Book V 13.03.2012 Institute for Quality and Efficiency in Health

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Perampanel - Benefit assessment according to § 35a Social Code Book V

Perampanel - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Perampanel – Nutzenbewertung gemäß § 35a SGB V” [Version 1.0; Status: 13.12.2012]). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A12-12 Perampanel – Benefit assessment according to § 35a (...) Social Code Book V 1 Extract of dossier assessment A12-12 Version 1.0 Perampanel – Benefit assessment acc. to § 35a Social Code Book V 13.12.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Perampanel – Benefit assessment according to § 35a Social Code Book V Contracting agency: Federal Joint Committee Commission awarded on: 15.09.2012 Internal Commission No.: A12-12 Address of publisher

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Fingolimod - Benefit assessment according to § 35a Social Code Book V

: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel: +49-(0)221/35685-0 Fax: +49-(0)221/35685-1 E-mail: berichte@iqwig.de www.iqwig.de Extract of dossier assessment A11-23 Version 1.0 Fingolimod - Benefit assessment acc. to § 35a Social Code Book V 11.01.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Bernd Kieseier, Department of Neurology, Düsseldorf University Hospital IQWiG thanks the external (...) Fingolimod - Benefit assessment according to § 35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment (“Fingolimod – Nutzenbewertung gemäß § 35a SGB V” (Version 1.0; Status: 11.01.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding IQWiG Reports - Commission No. A11-23 Fingolimod – Benefit assessment according to § 35a

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>